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Stress Echocardiography
A 4-Year Experience From a Single-Center Cohort Study of 26,774 Patients
Sahar S. Abdelmoneim, MD, MSC,*‡ Mathieu Bernier, MD,* Christopher G. Scott, MS,†
Abhijeet Dhoble, MD, MPH,* Sue Ann C. Ness, RN,* Mary E. Hagen, RDCS,*
Stuart Moir, MD,* Robert B. McCully, MD,* Patricia A. Pellikka, MD,*
Sharon L. Mulvagh, MD*
Rochester, Minnesota; and Assiut, Egypt
O B J E C T I V E S We evaluated the short- and long-term safety of contrast agents during stress
echocardiography (SE).
B A C KG ROUND Concerns about contrast agent safety led to revised recommendations for product
use in the U.S.
METHOD S We studied 26,774 patients who underwent SE between November 1, 2003, and
December 31, 2007. The 10,792 patients who comprised the contrast cohort received second-generation
perﬂuorocarbon-based agents for left ventricular opaciﬁcation during SE. The noncontrast cohort
comprised 15,982 patients who had their ﬁrst SE in the same period but without contrast agents.
Short-term (72 h and30 days) and long-term (up to 4.5 years) end points were death and myocardial
infarction (MI). Cox regression models were used. Immediate contrast agent-related adverse effects were
also reported.
R E S U L T S The contrast cohort had older patients (mean [SD] age, 65.8 [12.1] years vs. 62.6 [14.1]
years; p  0.001), a higher percentage of males (57.4% vs. 52.8%, p  0.001), and higher-risk patients
compared with the noncontrast cohort. In addition, dobutamine SE patients had greater cardiac risk than
exercise SE patients. Abnormal SE ﬁndings in patients who received contrast agents were more frequent
(32.4% vs. 27.9%, p  0.001). The 2 cohorts had no statistical difference in the incidence of short-term
events (death and MI). Within 72 h, 1 patient in the contrast cohort and 2 patients in the noncontrast
cohort died (p 0.54); 3 in the contrast cohort and 7 in the noncontrast cohort had MI (p 0.92). Within
30 days, 37 patients (0.34%) in the contrast cohort and 57 patients (0.36%) in the noncontrast cohort
died (p  0.85); 17 patients (0.16%) in the contrast cohort and 16 patients (0.10%) in the noncontrast
cohort had MI (p 0.19). Adjusted hazard ratios were not different between cohorts for death (0.99; 95%
conﬁdence interval: 0.88 to 1.11) or MI (0.99; 95% conﬁdence interval: 0.80 to 1.22).
CONC L U S I O N S The use of contrast agents during SE was not associated with an increased
short-term or long-term risk of death or MI. (J Am Coll Cardiol Img 2009;2:1048–56) © 2009 by the
American College of Cardiology Foundation
From the *Division of Cardiovascular Diseases and the †Division of Biostatistics, Mayo Clinic, Rochester, Minnesota; and the
‡Division of Cardiovascular Diseases, Assiut University, Assiut, Egypt. Dr. Mulvagh has received research grants from
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1049pacification of the left ventricular cavity
enhances endocardial border detection
and improves the assessment of ventric-
ular chamber dimensions and regional sys-
olic function (1). A growing body of international
iterature has demonstrated the safety of contrast
gents (2,3). Recent concerns about the safety of
ltrasonographic contrast agents led to changes in
he recommendations for product use in the U.S.
he U.S. Food and Drug Administration (FDA)
mphasized the risks of serious cardiopulmonary
eactions and required that warnings be added to
he labeling of ultrasonographic contrast agents.
his action followed a post-marketing report of 4
eaths within 30 min of contrast agent administration,
hich were not clearly attributable to contrast agent
njection. Subsequently, on May 12, 2008, revised
abeling changes, including a relaxation of previous
arnings, were implemented by the FDA (4).
See page 1057
In the present study, we evaluated the safety of
ontrast agents used during stress echocardiography
SE) with exercise or dobutamine in a high-volume
chocardiography laboratory by comparing 2 cohorts:
with patients who underwent contrast SE and a
eference cohort of patients who underwent SE with-
ut contrast agents. The end points were death and
yocardial infarction (MI). We hypothesized that the
se of contrast agents would not result in additional
arm to patients undergoing stress testing.
E T H O D S
his retrospective cohort study was approved by the
ayo Clinic Institutional Review Board. Only
atients who approved the use of their medical
ecords for research were included in the cohorts.
dentiﬁcation of study cohorts. Using the Mayo Clinic
tress Echocardiography Database, we identified all
atients who underwent their first SE between No-
ember 1, 2003, and December 31, 2007. Patients
ho received contrast agents during SE comprised the
ontrast cohort. The remaining patients who had SE
n the same period but who did not receive contrast
gents comprised the reference cohort (the noncon-
rast cohort). A total of 3.6% of patients did not
rovide consent to use their medical records and thus
ere excluded from study cohorts.
ontrast agents. The 2 contrast agents used were
econd-generation perfluorocarbon-based agents:
ptison (GE Healthcare, Princeton, New Jersey) tnd Definity (Lantheus Medical Imaging, North
illerica, Massachusetts). Contrast agents were ad-
inistered for left ventricular opacification accord-
ng to the American Society of Echocardiography
ask Force on Standards and Guidelines for the
se of Ultrasonic Contrast in Echocardiography
5). The contrast agents were administered in ac-
ordance with the package inserts.
E protocol. Patients in both groups had SE with
obutamine or exercise. Dobutamine SE was per-
ormed according to a standard protocol as previ-
usly described (6). For exercise SE, the symptom-
imited Bruce protocol was performed according to
standard protocol (7). Commercially available
ltrasound systems were used: SONOS 7500 or
E33 (Philips Medical Systems, Andover, Massa-
husetts), ACUSON Sequoia 512 (Siemens Med-
cal Solutions, Mountain View, California), and
ivid 7 (GE Healthcare, Princeton, New Jersey).
ll studies were recorded on videotape and digitized
or storage. Regional wall motion abnormal-
ties were interpreted with the use of video-
aped and digitized images according to
he standard 16-segment model. The 12-
ead electrocardiography and blood pres-
ure were monitored continuously.
ata collection and outcome measure-
ents. Patient demographic and SE data
ere prospectively recorded. The primary
utcome of this study was the short-term
afety of the contrast agents used. End
oints were death (due to any cause or to
cardiac event) and MI within 72 h and
0 days after SE. The secondary outcome
as the long-term safety of contrast agent use and
he time to the end point (death or MI) occurring
p to 4.5 years. Arrhythmias, including supraven-
ricular tachycardia, atrial fibrillation, and ventricu-
ar tachycardia (VT), were also reported. Sustained
T was defined as a regular wide QRS complex and
tachycardia of more than 100 beats/min that
asted for 30 s or more or caused hemodynamic
ollapse and that required medical or electrical
herapy. Nonsustained VT was defined as VT for 3
r more beats but with a duration of less than 30 s.
n addition, we prospectively documented adverse
ffects related to the use of contrast agents in 2007.
Deaths were identified by first searching the SE
atabase and the Mayo Clinic Death Database for
he same patients. Then, a thorough chart review
as conducted to confirm the death and the date of
ccurrence in relation to contrast agent administra-
A B B
A N D
CI c
FDA
Admin
HR
ICD-9
Classi
Ninth
MI
SE s
VTion. Similar measures were taken to identifR E V I A T I O N S
A C R O N YM S
onfidence interval
U.S. Food and Drug
istration
hazard ratio
 International
fication of Diseases-
Revision
myocardial infarction
tress echocardiographyy MI.
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1050e used the International Classification of
iseases-Ninth Revision (ICD-9) code. Chart re-
iews were conducted of all patients reported to
ave MI after SE.
tatistical analysis. For categorical variables, num-
ers of patients and proportions of the cohorts are
resented; differences between cohorts were tested
y using the Pearson chi-square test or Fisher exact
est, as appropriate. For continuous variables, mean
nd standard deviation are presented; differences
etween groups were tested by using the 2-sample t
est. Survival was estimated using the Kaplan-Meier
ethod. Multivariate Cox proportional hazards re-
ression models were used to test for differences in
ong-term outcomes after adjusting for known con-
ounders. We reported the annualized rates of
ombined events in both cohorts. In addition,
omparison of long-term outcomes between pa-
ients receiving contrast and those not receiving
ontrast was performed by propensity matching
nalysis. A logistic regression model was fit includ-
ng all relevant variables and propensity for receiv-
ng contrast as calculated from this model. Each
atient receiving contrast was matched on propen-
ity score to patients not receiving contrast. To
nsure that a good match was made, the maximal
llowable difference in propensity score was 0.25
tandard deviations. In all analyses, significance was
29,759 Pat
10,792 Included in
contrast cohort
H
6,516 (60.4
Had dobutami
4,276 (39.6%)
Had exercise SE
Indication for SE
Chest pain or 40.0%
  dyspnea (or both)
Known CAD 10.5%
Preoperative 34.5%
  evaluation
Suggested CAD 9.0%
Miscellaneous 6.0%
Figure 1. Flowchart of the Study Population (November 1, 2003
Patients in the contrast cohort received contrast agents during stre
receive contrast agents during SE. Patients underwent SE with dobu
electrocardiograms and coronary calciﬁcation on cardiac electron bet at a 2-sided p value of 0.05. All analyses were (erformed with SAS version 9.1 software (SAS
nstitute, Cary, North Carolina).
E S U L T S
uring the study period, 29,759 patients under-
ent SE; for 26,774 of these patients, the SE was
heir first at Mayo Clinic, Rochester, Minnesota
Fig. 1). The contrast cohort included 10,792 pa-
ients (4,276 had exercise SE and 6,516 had dobut-
mine SE; 86% received Definity contrast agent,
nd 14% received Optison contrast agent). The
oncontrast cohort included 15,982 patients (9,738
ad exercise SE and 6,244 had dobutamine SE)
ho had their first SE in the same period but did
ot receive contrast agents. Patients in the contrast
ohort were at greater risk of coronary artery disease
han those in the noncontrast cohort, and more
atients in the dobutamine SE group had greater
ardiac risk compared with patients who underwent
xercise SE (Tables 1 and 2). Compared with the
oncontrast cohort, the contrast cohort included
ore patients with abnormal SE for regional wall
otion abnormalities (32.4% vs. 27.9%; p 0.001).
hort-term safety of contrast SE. Even though it
ncluded higher-risk patients, the contrast cohort
ad percentages of deaths and MIs that were
omparable to those of the noncontrast cohort
ts had SE
18,967 Included in
noncontrast cohort
15,982 Included in
noncontrast cohort
2,985 Excluded
(had repeated SE)
6,244 (39.1%)
Had dobutamine SE
8 (60.9%)
xercise SE
E
Indication for SE
Chest pain or 41.0%
  dyspnea (or both)
Known CAD 8.0%
Preoperative 27.0%
  evaluation
Suggested CAD 15.0%
Miscellaneous 9.0%
rough December 31, 2007)
chocardiography (SE). Patients in the noncontrast cohort did not
ine or exercise. Miscellaneous indications were previous abnormal
computed tomography. CAD  coronary artery disease.ien
9,73
ad e
%)
ne S
, Th
ss e
tamTable 3). Within 72 h after SE, 1 patient in the
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1051ontrast cohort and 2 patients in the noncontrast
ohort died (p  0.54). The patient in the contrast
ohort who died was a 76-year-old woman with
iabetes mellitus who underwent dobutamine SE in
preoperative evaluation for repair of a mycotic
ortic aneurysm. SE results were normal, with no
eported adverse effects from contrast agents. The
atient died of cardiac and multiorgan failures on
ostoperative day 2 (48 h after SE). Within 72 h
fter SE, 3 patients in the contrast cohort and 7 in
he noncontrast cohort had MI (p  0.92). All 3
atients in the contrast cohort had dobutamine SE
1 received Definity; 2 received Optison).
Within 30 days after SE, 37 patients (0.34%) in the
ontrast cohort died and 57 patients (0.36%) in the
oncontrast cohort died (p 0.85). Of the deaths due
o cardiac causes, 10 were in the contrast cohort and
Table 1. Clinical Characteristics of Patients in the
Study Cohorts
Variable
Contrast*
(n  10,792)
Noncontrast
(n  15,982) p Value
Age, yrs 65.8 (12.1) 62.6 (14.1) 0.001
SE type 0.001
Dobutamine 6,516 (60.4%) 6,244 (39.1%)
Exercise 4,276 (39.6%) 9,738 (60.9%)
Male 6,194 (57.4%) 8,433 (52.8%) 0.001
BMI, kg/m2 31.2 (6.2) 27.0 (4.9) 0.001
Diabetes mellitus 2,808 (26.0%) 2,380 (14.9%) 0.001
Hypertension 7,376 (68.3%) 8,664 (54.2%) 0.001
Hyperlipidemia 7,299 (67.6%) 9,276 (58.0%) 0.001
Family history of
premature CAD
3,912 (36.2%) 5,561 (34.8%) 0.16
Prior MI 1,474 (13.7%) 1,485 (9.3%) 0.001
Prior CABG 1,384 (12.8%) 1,101 (6.9%) 0.001
EF at rest, % 59.3 (8.0) 59.8 (7.9) 0.001
EF at stress, % 69.1 (12.3) 69.2 (13.5) 0.73
WMSI at rest 1.12 (0.28) 1.10 (0.27) 0.001
WMSI at peak stress 1.16 (0.32) 1.15 (0.32) 0.001
Resting HR (beats/min) 71.1 (13.1) 72.8 (13.4) 0.001
Peak HR (beats/min) 136.2 (19.2) 141.6 (23.0) 0.001
Resting SBP (mm Hg) 133.5 (20.6) 130.9 (21.8) 0.001
Peak SBP (mm Hg) 150.6 (30.7) 157.0 (29.8) 0.001
Resting DBP (mm Hg) 75.6 (11.1) 75.4 (10.9) 0.02
Peak DBP (mm Hg) 74.2 (14.6) 76.4 (14.3) 0.001
Follow-up, yrs 1.11 (1.09) 1.37 (1.30) 0.001
The 26,774 patients included in the study underwent SE at the Mayo Clinic
Stress Echocardiography Laboratory from November 2003 through December
2007. Patients in the contrast cohort received contrast agents, and patients in
the noncontrast cohort did not. Continuous data are presented as mean (SD);
categorical data as number of patients and percentage of sample. *Mean
dose (SD) of Deﬁnity (diluted solution of 1 ml in 9 ml of saline) is 6.04 (6.53)
ml and Optison is 2.09 (1.00) ml.
BMI  body mass index; CABG  coronary artery bypass graft; CAD 
coronary artery disease; DBP  diastolic blood pressure; EF  ejection
fraction; HR  heart rate; MI  myocardial infarction; SBP  systolic blood
pressure; SE  stress echocardiography; WMSI  wall motion score index.1 were in the noncontrast cohort (p 0.23). Within w0 days after SE, MI was reported in 17 patients
0.16%) in the contrast cohort and in 16 patients
0.10%) in the noncontrast cohort (p  0.19).
rrhythmias and contrast SE. The overall incidence of
rrhythmias during SE was low in both cohorts.
upraventricular tachycardias and atrial fibrillation
ccurred in 30 patients (0.28%) in the contrast cohort
nd in 34 patients (0.21%) in the noncontrast cohort
p  0.31). Ventricular tachycardia occurred in 11
atients (0.10%) in the contrast cohort and in 7
atients (0.04%) in the noncontrast cohort (p 0.09).
n the contrast cohort, 2 patients had sustained VT, 2
ad ventricular fibrillation, and 7 had nonsustained
T. In the noncontrast cohort, 2 patients had sus-
ained VT and 5 had nonsustained VT.
There was no significant difference between the
roportion of patients in each cohort who had
entricular arrhythmias: with dobutamine SE, 10
0.15%) in the contrast cohort and 6 (0.09%) in the
oncontrast cohort (p  0.46); and with exercise
E, 1 (0.02%) in the contrast cohort and 1 (0.01%)
n the noncontrast cohort (p  0.52).
ong-term safety of contrast SE. Of the 10,792 pa-
ients in the contrast cohort, 841 patients had an
vent during follow-up (734 who had dobutamine
E and 107 who had exercise SE): 658 patients
ied (590 who had dobutamine SE and 68 who had
xercise SE) and 183 had MI (144 who had
obutamine SE and 39 who had exercise SE). Of
he 15,982 patients in the noncontrast cohort, 1,247
atients had an event during follow-up (988 who
ad dobutamine SE and 259 who had exercise SE):
78 died (803 who had dobutamine SE and 175
ho had exercise SE), and 269 had MI (185 who
ad dobutamine SE and 84 who had exercise SE).
or patients who had dobutamine SE, the annual-
zed event rate for the combined events of death and
I in the contrast cohort was 9.6% (95% confi-
ence interval [CI]: 8.9% to 10.3%) compared with
0.9% in the noncontrast cohort (95% CI: 10.2% to
1.6%). For patients who had exercise SE, the
nnualized event rate for combined events of death
nd MI in the contrast cohort was 2.2% (95% CI:
.8% to 2.6%) compared with 1.9% (95% CI: 1.6%
o 2.1%) in the noncontrast cohort.
Figure 2 presents Kaplan-Meier curves for sur-
ival free from death or MI for the dobutamine and
xercise SE subgroups. After adjustment for known
onfounders, no differences in the hazard ratios
HRs) for the events were observed between the
ontrast and noncontrast cohorts (Table 4). As a
econdary analysis; 7,654 contrast patients (71%)
ere propensity matched with patients not receiv-
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1052ng contrast. Analysis in this matched population
howed no evidence of an increased risk of death
HR: 0.99, 95% CI: 0.87 to 1.12, p  0.89) or MI
HR: 0.97, 95% CI: 0.76 to 1.23, p  0.79) for
atients receiving contrast.
dverse effects related to contrast agents. Contrast
gent-related complications in SE studies were
onsistently documented electronically in the data-
ase starting in January 2007. Among the 3,071
atients who underwent contrast SE in 2007 (1,819
Table 2. Clinical Characteristics of Patients Who Had Dobutamin
Variable
Dobutamine SE (n 
Contrast*
(n  6,516)
Noncont
(n  6,2
Age (yrs) 68.1 (11.8) 67.9 (13.
Male 3,613 (55.4%) 3,081 (49.
BMI, kg/m2 31.8 (6.7) 27.4 (5.6
Diabetes mellitus 2,120 (32.5%) 1,516 (24.
Hypertension 4,836 (74.2%) 4,233 (67.
Hyperlipidemia 4,341 (66.6%) 3,521 (56.
Family history of premature CAD 2,265 (34.8%) 1,971 (31.
Prior MI 1,028 (15.8%) 844 (13.
Prior CABG 952 (14.6%) 623 (10.
EF at rest (%) 59.1 (8.7) 58.9 (10.
EF at stress (%) 70.1 (13.9) 69.5 (12.
WMSI at rest 1.14 (0.31) 1.17 (0.3
WMSI at peak stress 1.18 (0.34) 1.21 (0.3
Resting HR (beats/min) 68.6 (12.0) 69.7 (12.
Peak HR (beats/min) 131.6 (14.9) 130.8 (16.
Resting SBP (mm Hg) 135.9 (21.4) 137.8 (23.
Peak SBP (mm Hg) 139.8 (29.5) 142.9 (31.
Resting DBP (mm Hg) 75.1 (11.2) 75.2 (11.
Peak DBP (mm Hg) 70.7 (14.5) 71.9 (15.
Follow-up (yrs) 1.1 (1.1) 1.4 (1.3
The 26,774 patients included in the study underwent SE at the Mayo Clinic St
Patients in the contrast cohort received contrast agents, and patients in the no
data as number of patients and percentage of sample. *During dobutamine SE:
ml and Optison is 2.41 (1.01) ml. †During exercise SE: mean dose (SD) of Deﬁn
(0.73) ml.
Abbreviations as in Table 1.
Table 3. Death and MI After Stress Echocardiography
Variable
Dobutamine SE (n 
Contrast
(n  6,516)
Noncontras
(n  6,244
Death within 72 h 1 (0.02%) 2 (0.03%)
Death within 30 days 35 (0.5%) 51 (0.8%)
Cardiac death within 30 days 9 (0.1%) 10 (0.2%)
MI within 72 h 3 (0.05%) 4 (0.06%)
MI within 30 days 15 (0.2%) 12 (0.2%)
The 26,774 patients included in the study underwent SE at the Mayo Clinic St
Patients in the contrast cohort received contrast agents, and patients in the non
percentage of sample.
Abbreviations as in Table 1.ad dobutamine SE and 1,252 had exercise SE),
ontrast agents were suspected to be the cause of
dverse reactions in 68 (2.2%), and a definite
elation with contrast agent infusion was estab-
ished in 41 of the 3,071 patients (1.3%). Backache
lone was reported in 19 of 3,071 patients (0.62%),
eadache alone in 16 (0.52%), and both in 4
atients (0.13%). Transient wheezing in the upper
irway without urticaria was reported in 1 patient
0.03%) undergoing dobutamine SE. Urticaria or
r Exercise Stress Echocardiography
,760) Exercise SE (n  14,014)
p Value
Contrast†
(n  4,276)
Noncontrast
(n  9,738) p Value
0.28 62.2 (11.8) 59.3 (13.7) 0.001
0.001 2,581 (60.4%) 5,352 (55.0%) 0.001
0.001 30.4 (5.2) 26.8 (4.5) 0.001
0.001 688 (16.1%) 864 (8.9%) 0.001
0.001 2,540 (59.4%) 4,431 (45.5%) 0.001
0.001 2,958 (69.2%) 5,755 (59.1%) 0.001
0.001 1,647 (38.5%) 3,590 (36.9%) 0.17
0.003 446 (10.4%) 641 (6.6%) 0.001
0.001 432 (10.1%) 478 (4.9%) 0.001
0.44 59.6 (6.6) 60.4 (6.1) 0.001
0.006 67.6 (9.2) 6.90 (13.8) 0.001
0.001 1.08 (0.23) 1.06 (0.19) 0.001
0.001 1.14 (0.29) 1.11 (0.26) 0.001
0.001 75.0 (13.8) 74.7 (13.6) 0.69
0.005 143.1 (22.6) 148.4 (24.0) 0.001
0.001 130.0 (19.0) 126.5 (19.8) 0.001
0.001 167.0 (24.4) 165.8 (25.1) 0.002
0.82 76.5 (10.8) 75.5 (10.6) 0.001
0.001 79.5 (13.0) 79.2 (12.9) 0.09
0.001 1.1 (1.1) 1.4 (1.3) 0.001
Echocardiography Laboratory from November 2003 through December 2007.
trast cohort did not. Continuous data are presented as mean (SD); categorical
n dose (SD) of Deﬁnity (diluted solution of 1 ml in 9 ml of saline) is 7.71 (7.75)
iluted solution of 1 ml in 9 ml of saline) is 3.46 (2.22) ml and Optison is 1.58
60) Exercise SE (n  14,014)
p Value
Contrast
(n  4,276)
Noncontrast
(n  9,738) p Value
0.54 0 (0.0%) 0 (0.0%) 0.99
0.05 2 (0.05%) 6 (0.1%) 0.73
0.26 1 (0.02%) 1 (0.01%) 0.71
0.72 0 (0.0%) 3 (0.03%) 0.25
0.64 2 (0.05%) 4 (0.04%) 0.88
Echocardiography Laboratory from November 2003 through December 2007.
trast cohort did not. Categorical data are presented as number of patients ande o
12
rast
44)
2)
3%)
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1053ives (on limbs and thorax) and swelling in the
outh were reported in 1 patient (0.03%) under-
oing exercise SE and were resolved within 15 min
ith intravenous administration of diphenhydra-
ine and subcutaneous administration of 0.5 ml of
pinephrine (1:1,000). Other side effects included
bdominal pain in 1 patient (0.03%) and throat
ingling in 1 patient (0.03%). The adverse reactions
hought to be caused by concomitant infusion of
ontrast agent and dobutamine were chest pain in
4 patients (0.78%), nausea and vomiting in 3
atients (0.10%), and shivering and tremors in 5
atients (0.16%).
I S C U S S I O N
o our knowledge, our cohort study is the largest to
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Figure 2. Survival Free of Major Cardiovascular Events
Kaplan-Meier survival curves presenting survival free of major cardi
years of follow-up for the dobutamine stress echocardiography (SE)
contrast agents during SE and patients in the noncontrast cohort d
infarction. p values are reported from the unadjusted model. After
ratios for the events were observed between the contrast and noncddress the safety of contrast agents used during aE. During short- and long-term follow-up, pa-
ients who had undergone SE with contrast agents
ere not at increased risk of death or MI compared
ith those who had not received contrast agents.
his was evident even though patients who re-
uired contrast agents had greater cardiovascular
isks. The large number of patients included in the
resent study allowed adjustments for known risk
actors that might confound the association be-
ween the use of a contrast agent as a risk factor and
he occurrence of cardiovascular events. Finally,
ontrast agent-related side effects were minor and
nfrequent. Recently, concerns about the safety of
ltrasonographic contrast agents led to changes in
he recommendations for product use in clinical
ractice (4).
In the medical literature, the 2 main concerns
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cular events including death and myocardial infarction over 4
exercise SE subgroups. Patients in the contrast cohort received
ot. (A) Survival free of death. (B) Survival free of myocardial
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1054rast agents in echocardiography are associated
ostly with imaging at a high mechanical index.
ne study reported the possibility of an increased
requency of premature ventricular contractions,
hich was hypothesized to be related to the
onthermal bioeffects of the ultrasound field (8).
owever, a subsequent study did not detect any
ncrease in the frequency of premature ventricular
ontractions during or after imaging at a high
echanical index (9). The other main concern is
he possibility of vascular injury and cardiac
njury. This concern was addressed in a recent
tudy that reported on the subclinical release of
ardiac biomarkers in humans after imaging at a
igh mechanical index (10). However, another
tudy reported that the use of contrast agent
chocardiography is not associated with risk of
yocardial damage (11). In a large study, Tsutsui
t al. (12) compared 1,486 patients who under-
ent dobutamine SE with contrast agents at a
ow mechanical index and 1,012 patients who
nderwent conventional dobutamine SE without
ontrast agents; no difference existed between the
groups in the incidence of nonsustained VT,
ustained VT, or supraventricular tachycardia. In
ur study, the occurrence of arrhythmias in the
ontrast cohort was comparable to the occurrence
n the noncontrast cohort; this similarity can be
xplained by the use of imaging at a low mechan-
cal index in most of the patients.
Contrast agent-related adverse effects in the
resent study were generally minor. Some of these
ide effects can be attributed to contrast agent
dministration, as evidenced by their reversal after
ecreasing the dose or discontinuing the adminis-
Table 4. Hazard Ratios for Death or MI
Death
Variable
Unadjusted HR
(95% CI)
Ad
Age at SE 1.05 (1.05–1.06) 1.0
Male 1.54 (1.40–1.71) 1.4
BMI 0.96 (0.95–0.97) 0.9
EF at rest 0.96 (0.96–0.97) 0.9
Diabetes mellitus 1.75 (1.58–1.95) 1.4
Previous MI 2.24 (1.99–2.52) 1.2
Known CAD 0.88 (0.74–1.03) 0.6
Abnormal SE 2.00 (1.80–2.21) 1.1
Dobutamine study 6.48 (5.66–7.43) 5.0
Contrast agents used 1.22 (1.11–1.35) 0.9
The 26,774 patients included in the study underwent SE at the Mayo Clinic Str
CI  conﬁdence interval; HR  hazard ratio; other abbreviations as in Table 1ration of the contrast agent. Other side effects, ancluding chest pain, arrhythmias, and shortness of
reath, can be linked to the sympathomimetic effect
f pharmacologic stress. Nevertheless, the safety of
tress testing has been demonstrated in several
ituations, with the overall incidence of side effects
eing small (13). In addition, the incidence of acute
naphylactoid reaction in our study was 0.03% (in
pproximately 3 of 10,000 patients), which is in
greement with the results from previous studies
14,15). In 2008, there was considerable debate
bout the safety of contrast agents in response to the
DA black box warnings. Both single center and
arge multicenter retrospective analyses have subse-
uently demonstrated a good safety profile and
isk/benefit ratio for ultrasound contrast agents
14–21) (Table 5).
The main limitation of the present study is that
ata analysis was retrospective; however, data col-
ection and data entry in the SE Database are
ngoing processes that are done prospectively. MI
nd death were selected as the main end points of
he study because they can be identified objectively
nd are easily retrievable from the medical records
ith high accuracy and precision. Another limita-
ion is the dependence on the ICD-9 codes for the
etrieval of the outcome; however, use of these
odes allowed an objective and unbiased method of
etermining the outcome. Contrast agent-related
dverse effects were directly entered into the Stress
chocardiography Database as of January 2007. We
sed these data to avoid underestimating side ef-
ects in previous years, which lacked standardized
ocumentation.
The present study has many strengths. The large
ample size, the cohort design, and the enormous
MI
ted HR
CI)
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
03–1.04) 1.04 (1.03–1.05) 1.02 (1.01–1.03)
33–1.65) 1.34 (1.11–1.62) 1.24 (1.01–1.52)
94–0.96) 0.99 (0.98–1.01) 0.98 (0.96–1.00)
98–0.99) 0.97 (0.96–0.98) 0.99 (0.98–1.00)
29–1.63) 1.89 (1.55–2.31) 1.51 (1.21–1.88)
11–1.46) 1.71 (1.35–2.18) 0.98 (0.75–1.29)
56–0.82) 1.18 (0.89–1.57) 1.02 (0.75–1.39)
03–1.32) 2.51 (2.07–3.04) 1.88 (1.51–2.35)
37–5.92) 3.03 (2.46–3.72) 2.50 (1.99–3.16)
88–1.11) 1.21 (1.00–1.46) 0.99 (0.80–1.22)
chocardiography Laboratory from November 2003 through December 2007.jus
(95%
4 (1.
8 (1.
5 (0.
8 (0.
5 (1.
7 (1.
8 (0.
7 (1.
9 (4.
9 (0.
ess Emount of information about the risk factors and
Table 5. Previous Reports on the Safety of Ultrasound Contrast Agents in 2008
Kusnetzky et al.,
2008 (16)
Herzog,
2008 (15)
Wei et al.,
2008 (14)
Gabriel et al.,
2008 (17)
Main et al.,
2008 (18)
Shaikh et al.,
2008 (19)
Dolan et al.,
2009 (20)
Aggeli et al.,
2008 (21)
Site(s) 1* 1† 13‡ 1§ Premier perspective
database
1¶ 3# 1**
Number of
patients
18,671 112,776 858,626 9,798 4,300,966 5,069 66,220 5,250
Population
included
Hospitalized
patients
Outpatients
Inpatients
ICU patients
Outpatients
Inpatients
Outpatients in 95% of
studies
Hospitalized patients Outpatients Outpatients
Inpatients
Outpatients
Type of echo
study
Rest TTE Rest TTE
SE
Rest TTE
SE
General
ultrasound
SE Rest TTE SE Rest TTE
SE
SE
Number of
patients:
contrast vs.
noncontrast
6,196 vs. 12,475 Contrast 16,025
vs. 0
78,383 vs. 780,243 4,786 vs. 5,012 58,254 vs. 4,242,712 2,914 vs. 2,155 42,408 vs. 23,812 Contrast 5,250 vs. 0
Outcome of
interest
Death 24 h Adverse events
within 30 min
Adverse events
within 30 min
Death 24 h
Serious adverse events
within 30 min
Death 24 h Serious adverse events after
contrast administration
Death and MIs within
30 min, 24 h, long-
term outcome
Serious adverse events after
or within 24 h of contrast
administration CTCAE
Event rate (%) Contrast vs.
noncontrast:
deaths 26
(0.42%) vs.
46 (0.37%),
p  0.60
No fatalities
20 events were
recorded,
4 (0.031%)
[95% CI:
0.01%–0.08%]
serious
nonfatal
reactions
No fatalities
8 (0.01%) serious
nonfatal
reactions;
of these,
4 (0.006%)
were severe
anaphylactoid
reactions
Contrast vs.
noncontrast:
deaths; 0 (0%) vs.
2 (0.04%), p  0.1
Serious adverse events;
0.19% vs. 0.17%,
p  0.7
Sustained VT; 8 (0.2%)
vs. 8 (0.1%),
p  0.32
Cardiac arrest;
2 (0.04%) vs.
2 (0.04%),
p  0.96
Contrast vs.
noncontrast:
deaths 616
(1.06%) vs.
45,789 (1.08%),
p  0.613
With adjusted odds
ratio of 0.76,
[95% CI:
0.70–0.82]
No sustained VT, VF,
cardiac arrest, or death in
either group
Contrast vs. noncontrast:
MI in 1 vs. 0
anaphylactoid reaction
in 1 vs. 0, p  0.51
Signiﬁcant arrhythmias in
2.1% vs. 1.9%, p  0.8
No deaths or MIs within
30 min in either
group 24 h
1 death and 5 nonfatal
MIs in contrast
30 days contrast vs.
noncontrast:
deaths 37 (0.34%) vs.
62 (0.39%), p  NS
MIs 68 (0.63%) vs. 73
(0.46%), p  NS
Median follow-up 25
months in contrast:
deaths 273 (4.4%)
MIs 237 (3.9%)
No fatalities
No MI
Sustained VT or VF requiring
resuscitation in 2 (0.04%)
Sustained VT not requiring
resuscitation in 10 (0.18%)
Nonsustained VT in
18 (0.34%)
Anaphylactoid reactions in
23 (0.44%) not requiring
hospitalization
*Saint Luke’s Health System, Kansas City, Missouri. †Hennepin County Medical Center, Minneapolis, Minnesota. ‡From the Oregon Health and Science University, Portland, Oregon; Mayo Clinic, Rochester, Minnesota; Baptist Memphis Department
of Echocardiography, Memphis, Tennessee; Boston Medical Center, Boston, Massachusetts; Cleveland Clinic, Cleveland, Ohio; Foothills Medical Centre, Calgary, Alberta, Canada; Hennepin Heart Center at Hennepin County Medical Center, University
of Minnesota, Minneapolis, Minnesota; Methodist DeBakey Heart and Vascular Center, Houston, Texas; North Kansas City Hospital, North Kansas City, Missouri; St. Luke’s-Roosevelt Hospital Center, Columbia University College of Physicians & Surgeons,
New York, NY; University of Nebraska Medical Center, Omaha, Nebraska; Vanderbilt Heart and Vascular Institute, Nashville, Tennessee; and the University of Chicago, Chicago, Illinois. §Cleveland Clinic, Cleveland, Ohio. Premier Perspective Database
is the largest United States hospital-based database and contains information from approximately 5.5 million patient discharges per year from not-for-proﬁt, nongovernmental, community and teaching hospitals, and health systems. ¶The Methodist
Hospital and the Methodist DeBakey Heart and Vascular Center Imaging Institute, Houston, Texas. #Saint Louis University Hospital, St. Louis, Missouri; University of Nebraska Medical Center, Omaha, Nebraska; and the Mayo Clinic, Rochester, Minnesota.
**University of Athens, First Cardiology department, Hippokration Hospital, Athens, Greece.
CI  conﬁdence interval; CTCAE  Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 3.0; ICU  intensive care unit; TTE  transthoracic echocardiography; VF  ventricular ﬁbrillation; VT  ventricular
tachycardia; other abbreviations as in Table 1.
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Contrast Agent Safety
1056nown confounders allowed thorough evaluation of
he association between contrast agent use and the
vents of interest by using multivariate Cox propor-
ional hazards regression analysis.
We believe that the results of the present study
re readily generalizable. The data are from a
eal-life, high-volume echocardiography laboratory
or primary care and referral practices. However, the
esults might not be valid for other populations
ecause of variations in clinical practice, clinical
ettings, or patient characteristics. Thus, furthercise echocardiography: techniques,
implementation, clinical applications, JAMA 2008;299;20O N C L U S I O N S
n summary, the present study showed that the use
f contrast agents during SE is not associated with
ncreased short-term or long-term risk of death or
I. The study also provided further evidence of the
afety of contrast agent use in echocardiography in
eneral and during SE in particular.
eprint requests and correspondence: Dr. Sharon L. Mul-
agh, Division of Cardiovascular Diseases, Mayo Clinic,
00 First Street SW, Rochester, Minnesota 55905.validation studies are needed. E-mail: smulvagh@mayo.edu.1
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